Expert Systems Reaches Key Milestone with Lomond Therapeutics

Expert Systems Achieves Milestone with Lomond Therapeutics in Drug Discovery

ROCKVILLE, Md., Oct. 16, 2024 /PRNewswire/ -- Expert Systems, recognized for its expertise in combining human and artificial intelligence to expedite drug discovery, is delighted to announce a significant achievement in its collaboration with Lomond Therapeutics. The U.S. Food and Drug Administration (FDA) has approved Lomond's Investigational New Drug (IND) application for a Phase 1 clinical trial of lonitoclax, a selective BCL-2 inhibitor, aimed at treating patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain low-grade lymphomas.

The cutting-edge AI platform developed by Expert Systems has played a crucial role in Lomond's preclinical processes. This platform has enhanced the speed and accuracy of identifying and selecting lonitoclax through sophisticated computational modeling, in silico evaluations, and thorough off-target pharmacology studies.

Bill Farley, Chief Business Officer at Expert Systems, commented on this accomplishment, stating, "This FDA clearance for Lomond's IND is a pivotal moment in our partnership. It underscores the robustness of our AI-driven platform in reducing risks associated with drug candidate selection and accelerating the development of groundbreaking treatments. We look forward to continuing our support for Lomond as lonitoclax progresses into clinical trials."

About Expert Systems, Inc.

Expert Systems, Inc. operates a highly advanced AI-driven platform aimed at speeding up drug discovery across preclinical and early development phases. Their platform provides a comprehensive solution, including target identification, virtual screening, non-clinical and clinical pharmacology, chemical liability evaluations, and toxicology assessments. By utilizing a blend of proprietary and publicly available databases, Expert Systems offers specialized tools to evaluate the intellectual property landscape and develop competitive drug intelligence strategies. This significantly reduces risks in the selection of drug candidates and facilitates their swift transition from in silico models to first-in-human trials.

Expert Systems has been crucial in launching Seed and Series A companies and has overseen more than 30 research and development programs in collaboration with financial investors and strategic partners throughout North America, Europe, and Australia.